tbuckley/cabot-search huggingface dataset:
Inaccurate Classification in: Statin Use and Hospitalization for Sepsis in Patients With Chronic Kidney Disease
Authors: Peter Pronovost, Marlene Miller, Robert Wachter
Journal: JAMA (2008)

mal details.For measures that lack national standards, such as those developed by individual hospitals, more information is needed to make biases transparent.A framework 1 based on the Users' Guides to the Medical Literature 2 has been developed to help health care organizations evaluate the validity of their quality measures.Rather than provide guidance on a specific measure, the framework provides guidance on estimating and reporting biases in quality and safety measures.Such a framework can initiate discussion of data elements that should be reported for quality measures.It must be coupled with additional research to identify evidence-based quality standards, determine the best strategy for enforcing standardized reporting, and evaluate the costs and benefits of reporting.
Commentaire de travail de C. Moreno et al., pp. 406
Journal: Endoscopy (2008)

See also: Transoral gastroplasty is safe, feasible, and induces significant weight loss in morbidly obese patients: results of the second human pilot studyEndoscopy 2008; 40(05): 406-413DOI: 10.1055/s-2007-995748
Methadone Maintenance
Authors: Robert A. Maslansky
Journal: JAMA (1976)

<h3>To the Editor.—</h3> Once again, Vincent Dole's wisdom and prescience has been heard (235:217-219,1976). In condemning the bureaucratization of the pharmacologic strategy of methadone maintenance, he has (and I'm sure with much personal sadness) shown how stultifying regulations can pervert a humane treatment concept. Dr Dole has always understood methadone's limitations and hazards. Never had he, nor for that matter, most of the early workers in the field, claimed a panacea was discovered. He points out that the regulations now in force lead to a pseudoprofessionalism; consequently, the zeal of pioneering has been lost, the fear of censure and liability has invidiously arrived, and those of us who worked in the earlier times have despaired and left the field. Pavlov and Skinner taught us that responses can be conditioned by a loop of stimulus and behavior. What boggles the mind is that the law enforcement people behave as though what
In Reply:
Authors: Jacques Bonneterre
Journal: Journal of Clinical Oncology (2005)

challenges of research on the cancer anorexia/weight-loss syndrome by commenting on the importance of clinically relevant end points, the need for compliance assessment, and the potential of early intervention.These are important points, and we acknowledge that each of these three "negative" trials may have limitations.However, any such limitations in their own right do not justify the use of EPA.After three large "negative" studies, the onus of demonstrating benefit now rests in the hands of proponents of EPA.These proponents must put forth critical new evidence to convince cancer patients, their families, and oncologists that this agent continues to be worthy of clinical investigation.For others of us who continue to observe the devastating decline of weight-losing cancer patients on a daily basis-despite their ingestion of EPA-containing supplements-we think it time to move on and study other agents.
MORE CRYSTALLINE ENZYMES
Journal: JAMA (1934)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Fibrinolysis During and After Extracorporeal Circulation
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Another African disaster.
Authors: C Gilks
Journal: BMJ (1993)

Electroacupuncture in fibromyalgiaED1TOR,-Several important issues arise from Christophe Deluze and colleagues' paper on electroacupuncture in fibromyalgia.'The use of electroacupuncture rather than ordinary acupuncture in this study is questionable.To treat musculoskeletal pain, manual manipulation of the needles is all that many experienced physicians consider to be necessary.2Indeed, excessive stimulation of the needles may exacerbate the symptoms.This and the unpleasantness of needle insertion (suggesting poor needling technique) led to an unusually high drop out rate in both the group given electroacu- puncture (17%) and the controls (15%) in the study.The authors also seem uncertain about the rationale for selecting acupuncture points; they say that they used "four common acupuncture points," but it is unclear exactly which points these were.The authors claim that "traditional acupuncture points" were used, and the hand point does seem to correspond to the Chinese acupuncture point Hegu (L14).The leg point, however, corresponds only approximately to the Chinese acupuncture point Zusanli (ST36), the location given being inaccurate.This point should be located by using a system of proportional measurement, which allows for differences in the size of patients.The correct distance below the inferior border of the patella is not 5 cm but 3 cun, which corresponds to the width of the patient's four fingers.Needle insertion into the tender points was avoided in this study.In treating myofascial pain, however, the best results are generally considered to be obtained by inserting the needles into the points of maximum tenderness, though electrical stimulation is usually unnecessary.Lastly, the points used in the control group cannot be regarded as suitable: electrical stimula- tion of needles only 2 cm from the real points is unlikely to be without some effect.The true efficacy of acupuncture may have been under- estimated, and further studies of higher quality are needed.
Experimental Leukemia
Authors: Paul H. Hattersley
Journal: JAMA (1969)

Most physicians see only a small group of leukemias in a lifetime of practice, but are profoundly affected by those they do see. Each patient presents his own difficult and eventually insoluble problems. Negative prognosis is inherent in the diagnosis. The practitioner, therefore, thinks of the leukemias of experimental animals as models which may some day lead to better understanding of the causes of these terrible diseases in man, to better methods of treatment, eventually perhaps even to means of cure and of prevention. Rich's<i>Experimental Leukemia</i>will therefore probably have little appeal to the average physician, or even to the clinical hematologist. The editor of this compendium of observations on leukemia in experimental animals has gone out of his way to avoid mention of human disease. Upton and Cosgrove, for instance, in their chapter on radiation-induced leukemia, make no mention of the extensive studies among the victims of the
Poster Session 1: Behavioral, Quality of Life, and Practice Issues
Authors: Xavier Adhoute, Paul Castellani, Guillaume Penaranda, Olivier Monnet, Herve Perrier, Bernard Pol, Cyril Muller, Arthur Laquiere, Valerie Oules, Patrick Beaurain, Christian Boustiere, Olivier Bayle, Marc Bourlière, Suzanne Polis, Ling Zhang, Amany Zekry, Ritin Fernandez, Anna Hefner, Cynthia Connelly, Kathy James, Catherine Hill, Preeti Reshamwala, Tarek Hassanein
Journal: Hepatology (2014)

Purpose : To analyze the impact of TIPS with covered stents on survival of patients with "severe" portal hypertension compared to a control group treated medically.To assess complications associated with implantation of the TIPS.Material and methods : 344 consecutive patients were hospitalized for decompensated cirrhosis (Child-Pugh B 60% / C 40%) from 01/2008 to 12/2012.Covered stent was implanted in 98 patients for refractory ascites or recurrent gastrointestinal bleeding.Assessment of median survival (MS) with and without TIPS, MS according to Child-Pugh score and after matching 1:1 (n=130) for age, Child-Pugh score, MELD score, presence of hepatocellular carcinoma HCC, to a control group having a first decompensation.Results :TIPS implantation was successful in 100% of rates.The mean portosystemic pressure gradient decreased from 18.5±4.5mmHg to 5.8±2.6 mmHg.MS of patients with TIPS (n=98) was 29.4 months [22-38.6]vs. 12.9 months [10.2-18.3]without TIPS (n=246), p=0.0015 ; MS of childpugh B patients with TIPS (n=69) was 38.6 months [29.4-48.7] vs. 19.1 months [14.1-35.3]without TIPS (n=137), p=0.0183;MS of child-pugh C patients with TIPS (n=29) was 17.4 months [10.1-25.3] vs. 8 months [6.2-11.2]without TIPS (n=109), p=0.22.TIPS was a prognostic variable associated with survival in univariate analysis (p=0.015).HCC, alcoholic hepatitis were more frequent in patients without TIPS (respectively 31% vs. 8%, p <.0001, 17% vs. 10%, p=0.05).After matching 1:1 for age (61 ±10), Child-Pugh score (B 66%, C 34%), MELD score (17.0±4.2) and presence of HCC (9%), esophageal varices grade 2 or 3 (p=0.003),refractory ascites (p=0.01), an increase in the portosystemic gradient (p=0.008) were significantly more frequent in the TIPS group.Median survival was 26 months in the TIPS group (n=65) vs. 27 months without TIPS (n=65), p=1.00.Median follow up was 12 months.Rate of infection did not differ between the 2 groups.Main complications of TIPS (recurrent encephalopathy 34%, stent dysfunction 24.5%, strangulated umbilical hernia 9%, congestive heart failure 7.5%) did not affect patient survival.Conclusion : in this series, TIPS with covered stents appears to improve the natural history of Child-Pugh B cirrhosis with recurrent decompensation.Conversely, decreasing portosystemic pressure gradient does not alter the progression of Child-Pugh C cirrhosis with prolonged decompensation.Earlier implementation of a tips should be discussed for some child-pugh B patients with recurrent ascites or gastrointestinal bleeding.
The aging stomach
Authors: M GUSLANDI
Journal: Gut (1998)

Editor,—After reading Lee and Feldman’s excellent article on the aging stomach ( Gut 1997; 41 :425–6), I have realised how many concepts we take for granted even in the absence of clear-cut scientific evidence. In their exhaustive review Lee and Feldman emphasise the paucity of human studies on the state of mucosal defence systems in the elderly. I actually had some data on file which have never been published as I felt that the results were “too obvious” to interest any medical journal. I can only blame myself for not searching … Dr Lee.
How Useful Are Cytomegalovirus Cultures in Patients with HIV Infection?
Authors: Michael P. Dube
Journal: Annals of Internal Medicine (1993)

Letters1 August 1993How Useful Are Cytomegalovirus Cultures in Patients with HIV Infection?Michael P. Dube, MD and Fred R. Sattler, MDMichael P. Dube, MDSearch for more papers by this author and Fred R. Sattler, MDSearch for more papers by this authorAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-119-3-199308010-00021 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR:We disagree that CMV blood cultures have no clinical utility and interpret the results of Zurlo and colleagues [1] to suggest that positive cultures have an important prognostic value. That 35% of their patients with viremia developed end-organ disease, after a mean of 84.1 days, suggests that these patients should be closely monitored in the ensuing months. A prospective study by Salmon and colleagues (2; not cited by Zurlo and colleagues) supports this approach. Fifty percent of patients with CMV viremia (14 of 28) followed for at least 6 months developed end-organ involvement compared with only 9.3% ...References1. Zurlo JJ, O'Neill D, Polis MA, Manischewitz J, Yarchoan R, Baseler M, et al. Lack of clinical utility of cytomegalovirus blood and urine cultures in patients with HIV infection. Ann Intern Med. 1993; 118: 12-7. Google Scholar2. Salmon D, Lacassin F, Harzic M, Leport C, Perronne C, Bricaire F, et al. Predictive value of cytomegalovirus viraemia for the occurrence of CMV organ involvement in AIDS. J Med Virol. 1990; 32: 160-3. Google Scholar Author, Article, and Disclosure InformationAffiliations: PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics 1 August 1993Volume 119, Issue 3Page: 247-249KeywordsAIDSBloodCytomegalovirus infectionFeversHIV infectionsProspective studiesRetinitisViremia ePublished: 15 August 2000 Issue Published: 1 August 1993 Copyright & PermissionsCopyright © 1993 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...
Developmental Neuropathology
Authors: Oriville T. Bailey
Journal: JAMA (1976)

In the past two decades, the advances in pediatric neuropathology have extended knowledge of central nervous system lesions in the perinatal period and early childhood to a degree hardly matched in any other field of pathology. Neuropathologists and pediatric neurologists have felt the need of a manageable volume covering these new contributions and placing them in relationship to traditional concepts. Numerous excellent monographs have dealt with segments of the field, but the few volumes attempting more general coverage have been disappointing. Despite the title, Friede's book covers most phases of pediatric neuropathology except neoplasms. As an introduction, there is a brief but useful chapter on the developing brain as its structure relates to lesions. The rest of the text is divided into three nearly equal parts—acquired lesions in infancy and childhood, malformations, and metabolic diseases. In dealing with so many diverse conditions in a single volume, some compromise must be
Bone Grafting.
Authors: G. J. Kaumheimer
Journal: JAMA (1896)

Milwaukee, Wis., April 11, 1896. <h3>To the Editor:</h3> —In your issue of April 4, p. 692 is an extract from the<i>Medical Press and Circular</i>, in regard to "An Unusual Case of Bone Grafting. Permit me to say that this is another illustration of the old saw, "A prophet is not without honor, save in his own country" and to call your attention to an article on this subject by Professor Senn, in the<i>Am. Jour. Medical Sciences</i>, September, 1889. Yours,
AUTHORITY IN MEDICINE.
Journal: JAMA (1901)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Demonstration of duck hepatitis B virus in bile duct epithelial cells: Implications for pathogenesis and persistent infection
Authors: A Nicoll
Journal: Hepatology (1997)

Hepatitis B virus (HBV) has been demonstrated in bile duct epithelial cells (BDEC) during chronic infection. The persistence of virus in BDEC may play an important role in disease pathogenesis, and may be at least partly responsible for the relapse phenomenon observed in antiviral treatments using nucleoside analogues. The aims of this study were to examine the morphological changes within the liver in the duck hepatitis B model following bile duct ligation (BDL), and to assess the effect of biliary hyperplasia upon viral DNA and proteins. Seven-day-old ducklings, congenitally infected with the duck hepatitis B virus (DHBV), were subject to BDL. The pathological and virological changes were then followed at 5, 10, 15, and 20 days after ligation. All results were compared with age-matched unligated control birds congenitally infected with DHBV. To assess the early morphological changes, additional animals were sacrificed at 1, 2, 3, and 4 days post-BDL. The proportion of DHBV-infected BDEC, was examined by immunohistochemistry and in situ hybridization. BDL induced rapid biliary hyperplasia, with a doubling time for BDEC of 1.3 days. The proliferated BDEC displayed immunohistochemical features identical to resting BDEC. More than 50% of BDEC in unligated controls, and more than 46% of proliferated BDEC in ligated animals were positive for DHBV DNA and structural proteins. The intensity of immunohistochemical staining and in situ hybridization signal in the BDEC was consistently greater than that of the hepatocytes, both before and after BDL. BDL induces biliary hyperplasia in the duck model, and BDEC division does not reduce the viral burden in infected cells.
Fluorescent bile acid derivatives: Relationship between chemical structure and hepatic and intestinal transport in the rat.
Authors: F Holzinger
Journal: Hepatology (1997)

Studies were performed to characterize hepatic and intestinal transport, as well as biotransformation during transport, of a spectrum of fluorescent bile acids containing a fluorophore attached to the side chain. The following two classes of compounds were studied: 1) aminofluorescein (amF) coupled directly to the carboxylic group of a bile acid which was cholic, ursodeoxycholic, or cholylglycine; and 2) nitrobenzoxadiazolyl (NBD) coupled to the ϵ-amino group of a lysine conjugated bile acid, which was cholic or ursodeoxycholic. Fluorescein, a cholephilic organic anion, was studied as a control. Fluorescent bile acids were synthesized and their structures confirmed by nuclear magnetic resonance and mass spectrometry. Using the biliary fistula rat, hepatic transport, biotransformation, and choleretic activity were defined; intestinal absorption was assessed by jejunal or ileal perfusion studies. All fluorescent bile acids had hepatic transport maxima about one-sixth that reported for cholyltaurine, but derivatives of cholylglycine were transported best. Bile acids underwent little (<5%) biotransformation during hepatocyte transport. Only the amF conjugate of cholylglycine had normal choleretic activity; other compounds were hypocholeretic or cholestatic. In contrast, fluorescein was well transported, was partly glucuronidated, and had normal choleretic activity. NBD-tagged, but not amF-tagged, bile acids were actively transported by the intestine (ileum > jejunum), and no fluorescent bile acid had passive intestinal permeability; NBD-tagged bile acids were biotransformed during intestinal transport (jejunum > ileum). We conclude that the structure of the fluorophore as well as that of the bile acid influences transport by the hepatocyte and enterocyte. These fluorescent bile acids differ from fluorescein in being impermeable to cell membranes and undergoing little biotransformation during hepatocyte transport. Of these fluorescent bile acids, cholylglycylamF has hepatocyte transport and choleretic properties most closely resembling those of a natural bile acid. (Hepatology 1997 Nov;26(5):1263-71)
Abstract 281: Sensitivity to splicing modulation of BCL2 family genes reveals cancer therapeutic strategies for splicing modulators
Authors: Daniel Aird, Teng Teng, Chia-Ling Huang, Ermira Pazolli, Deepti Banka, Kahlin Cheung-Ong, Cheryl Eifert, Craig Furman, Jeremy Wu, Michael Seiler, Silvia Buonamici, Peter Fekkes, Craig Karr, James Palacino, Eunice Park, Peter Smith, Lihua Yu, Yoshiharu Mizui, Markus Warmuth, Agustin Chicas, Laura Corson, Ping Zhu
Journal: Cancer Research (2019)

Abstract Dysregulation of RNA splicing by spliceosome mutations or in cancer genes is increasingly recognized as a hallmark of cancer. Small molecule splicing modulators have been introduced into clinical trials to treat solid tumors or leukemia bearing recurrent spliceosome mutations. Nevertheless, further investigation of the molecular mechanisms that may enlighten therapeutic strategies for splicing modulators is highly desired. Here, using unbiased functional approaches, we report that the sensitivity to splicing modulation of the anti-apoptotic BCL2 family genes is a key mechanism underlying preferential cytotoxicity induced by the SF3b-targeting splicing modulator E7107. While BCL2A1, BCL2L2 and MCL1 are prone to splicing perturbation, BCL2L1 exhibits resistance to E7107-induced splicing modulation. Consequently, E7107 selectively induces apoptosis in BCL2A1-dependent melanoma cells and MCL1-dependent NSCLC cells. Furthermore, combination of BCLxL (BCL2L1-encoded) inhibitors and E7107 remarkably enhances cytotoxicity in cancer cells. These findings inform mechanism-based approaches to the future clinical development of splicing modulators in cancer treatment. Citation Format: Daniel Aird, Teng Teng, Chia-Ling Huang, Ermira Pazolli, Deepti Banka, Kahlin Cheung-Ong, Cheryl Eifert, Craig Furman, Jeremy Wu, Michael Seiler, Silvia Buonamici, Peter Fekkes, Craig Karr, James Palacino, Eunice Park, Peter Smith, Lihua Yu, Yoshiharu Mizui, Markus Warmuth, Agustin Chicas, Laura Corson, Ping Zhu. Sensitivity to splicing modulation of BCL2 family genes reveals cancer therapeutic strategies for splicing modulators [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2019; 2019 Mar 29-Apr 3; Atlanta, GA. Philadelphia (PA): AACR; Cancer Res 2019;79(13 Suppl):Abstract nr 281.